Ipsen Sees First Mover Advantage In EU For Cabometyx In Liver Cancer

 
• By Sten Stovall
  
Liver
Ipsen's Cabometyx Gets EMA panel backing to treat hepatocellular carcinoma (HCC) • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip